GGrantIndex
← Search

CORE--PHARMACY

$109,325P30FY2004CANIH

Mayo Clinic, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

The long-term objective of the Pharmacology Shared Resource is to continue to provide critical pharmacologic support, services and expertise for Cancer Center investigators engaged in the development and evaluation of anticancer agents. The specific aims of the Shared Resource are to provide the necessary services and expertise for: 1) the conduct of clinical pharmacokinetic studies conducted through the vigorous Phase I and Phase II clinical trials programs in the Cancer Center 2) for the conduct of pharmacogenetic studies conducted in concert with Phase I, Phase II and other appropriate clinical trials and 3) for the conduct of preclinical pharmacology studies in support of Cancer Center investigator research. To accomplish these aims, the Shared Resource has extensive capabilities and expertise for the analysis of drugs and their metabolites in biological specimens, for the conduct of clinical and preclinical pharmacokinetic studies using those assay methodologies and for the analysis of pharmacokinetic data. In addition, the Shared Resource has expertise in the structural and pharmacologic characterization of metabolites and in the structural and pharmacologic characterization of metabolites. During the last two years, the Shared Resource has initiated development and implementation of genotyping assays for the conduct of pharmacogenetic studies focused on genes and protein products associated with response to anticancer agents. Genotyping assays for genes expressing wild-type and variant isoforms of many oxidative and conjugating enzymes are currently being conducted in conjunction with Phase I and Phase II protocols. Finally, the Shared Resource also offers pharmacologic methodology for a variety of preclinical studies to Cancer Center investigators. The availability of these services and associated expertise in a single facility has fostered an integrated approach to pharmacologic research in the Cancer Center.

View original record on NIH RePORTER →